RxNorm 2477899
etesevimab 35 MG/ML
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 2477899 unique identifier include: etesevimab 35 MG/ML (12538834).
RxNorm Atom ID: 12538834 - Semantic Clinical Drug Component
etesevimab 35 MG/ML
- RXCUI:
- 2477899 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12538834 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- etesevimab 35 MG/ML - Description of concept identifier
- Term Type (TTY):
- SCDC - Term type in source with name and description
- Term Type Name:
- Semantic Clinical Drug Component - Name of term type in source
- Term Type Description:
- Ingredient + Strength - Description of term type in source
- Code:
- 2477899 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom 12538834 Attributes
Property | Value | Explanation |
---|---|---|
RXN BOSS STRENGTH DENOM UNIT | ML | RXN Boss Strength Denom Unit |
RXN BOSS STRENGTH DENOM VALUE | 1 | RXN Boss Strength Denom Value |
RXN BOSS STRENGTH NUM UNIT | MG | RXN Boss Strength Num Unit |
RXN BOSS STRENGTH NUM VALUE | 35 | RXN Boss Strength Num Value |
RXN STRENGTH | 35 MG/ML | Strength plus unit of SCDC |
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Bamlanivimab and Etesevimab Injection
The combination of bamlanivimab and etesevimab injection is used to treat COVID-19 infection in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have mild to moderate COVID-19 symptoms. They are used in people who have certain medical conditions such as diabetes, immunosuppressive conditions, or kidney, heart, or lung disease that put them at higher risk for developing severe COVID-19 symptoms and/or needing to be hospitalized from COVID-19. Bamlanivimab and etesevimab are in a class called monoclonal antibodies. These medications work by blocking the action of a certain natural substance in the body to stop the spread of the virus.
[Learn More]
* Please review the disclaimer below.